Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exebacase - ContraFect

Next Previous
Drug Profile

Exebacase - ContraFect

Alternative Names: CF-301; Lysin CF-301

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Antibacterials; Endolysins; Enzymes; Recombinant proteins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacteraemia; Infections; Osteomyelitis; Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 04 Dec 2023 Discontinued - Phase-I for Infections (Treatment-experienced) in France (Intra-articular) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
  • 04 Dec 2023 Discontinued - Phase-I/II for Staphylococcal infections in France (Intra-articular) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
  • 04 Dec 2023 Discontinued - Phase-II for Bacteraemia (Adjunctive treatment) in United Kingdom, Italy, Russia, Spain, Chile, Bulgaria, Belgium, Czech Republic, France, Germany, Israel, Guatemala, Greece (IV) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top